Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

FGFR2 inhibitor RLY-4008

An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, FGFR2 inhibitor RLY-4008 binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:fibroblast growth factor receptor 2 inhibitor RLY-4008
Code name:RLY 4008
RLY-4008
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search